• Viralytics Ltd., of Melbourne, Australia, said it raised A$3.5 million (US$3.6 million) under its share purchase plan, accepting oversubscriptions above the A$3 million target. Funds will be used for working capital and for continuation of clinical research and development of Cavatak, an oncolytic virus candidate.
To read more on related topics, click on one of the words below.